RaQualia Pharma Inc
TSE:4579

Watchlist Manager
RaQualia Pharma Inc Logo
RaQualia Pharma Inc
TSE:4579
Watchlist
Price: 563 JPY 4.84% Market Closed
Updated: May 31, 2024

RaQualia Pharma Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

RaQualia Pharma Inc
Cost of Revenue Peer Comparison

Comparables:
4502
4568
4578
4519
4503

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
RaQualia Pharma Inc
TSE:4579
Cost of Revenue
-¥245.1m
CAGR 3-Years
-21%
CAGR 5-Years
-22%
CAGR 10-Years
-96%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cost of Revenue
-¥1.4T
CAGR 3-Years
-13%
CAGR 5-Years
-17%
CAGR 10-Years
-11%
Daiichi Sankyo Co Ltd
TSE:4568
Cost of Revenue
-¥415.3B
CAGR 3-Years
-7%
CAGR 5-Years
-3%
CAGR 10-Years
-4%
Otsuka Holdings Co Ltd
TSE:4578
Cost of Revenue
-¥626.2B
CAGR 3-Years
-12%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cost of Revenue
-¥334.9B
CAGR 3-Years
-8%
CAGR 5-Years
-5%
CAGR 10-Years
-5%
Astellas Pharma Inc
TSE:4503
Cost of Revenue
-¥292.5B
CAGR 3-Years
-6%
CAGR 5-Years
0%
CAGR 10-Years
1%

See Also

What is RaQualia Pharma Inc's Cost of Revenue?
Cost of Revenue
-245.1m JPY

Based on the financial report for Dec 31, 2023, RaQualia Pharma Inc's Cost of Revenue amounts to -245.1m JPY.

What is RaQualia Pharma Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-96%

Over the last year, the Cost of Revenue growth was -6%. The average annual Cost of Revenue growth rates for RaQualia Pharma Inc have been -21% over the past three years , -22% over the past five years , and -96% over the past ten years .